SomnoMed Beheer

Hoe is Amrita Blickstead's beloning veranderd ten opzichte van SomnoMed's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$624k	AU$167k	-AU$12m
Mar 31 2024	n/a	n/a	-AU$11m
Dec 31 2023	n/a	n/a	-AU$11m
Sep 30 2023	n/a	n/a	-AU$9m
Jun 30 2023	AU$91k	n/a	-AU$8m
Mar 31 2023	n/a	n/a	-AU$7m
Dec 31 2022	n/a	n/a	-AU$5m
Sep 30 2022	n/a	n/a	-AU$5m
Jun 30 2022	AU$91k	n/a	-AU$4m
Mar 31 2022	n/a	n/a	-AU$5m
Dec 31 2021	n/a	n/a	-AU$5m
Sep 30 2021	n/a	n/a	-AU$3m
Jun 30 2021	AU$32k	n/a	-AU$1m

Compensatie versus markt: De totale vergoeding ($USD 414.12K ) Amrita } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 304.34K ).

Compensatie versus inkomsten: De vergoeding van Amrita is gestegen terwijl het bedrijf verliesgevend is.

CEO

Amrita Blickstead

4.3yrs

Tenure

AU$624,323

Compensatie

Ms. Amrita Blickstead, MBA, BME, is Co-Chief Executive Officer and Executive Director of SomnoMed Limited. Ms. Blickstead was Non-Executive Director of SomnoMed Limited from August 24, 2020. Ms. Blickstead...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Amrita Blickstead	Co-CEO & Executive Director	no data	AU$624.32k	0.49% A$ 304.2k
Karen Borg	Co-CEO & Executive Director	no data	AU$693.50k	0.24% A$ 146.5k
Mark Harding	Vice President of Global Marketing	5.3yrs	AU$483.37k	0.067% A$ 41.2k
Matthew Conlon	Executive VP of Sales & Marketing - North America	5.1yrs	AU$427.31k	0% A$ 0
Marco Van Kleef	Vice President of Marketing & Sales - Europe	no data	AU$589.17k	geen gegevens
Terence Flitcroft	Company Secretary	29.8yrs	AU$35.38k	geen gegevens
Christopher Bedford	Vice President of Global Production and Product Development	no data	AU$128.07k	geen gegevens

5.3yrs

Gemiddelde duur

Ervaren management: Het managementteam van SOM is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Amrita Blickstead	Co-CEO & Executive Director	4.3yrs	AU$624.32k	0.49% A$ 304.2k
Karen Borg	Co-CEO & Executive Director	4yrs	AU$693.50k	0.24% A$ 146.5k
Michael Gordon	Non-Executive Director	4.3yrs	AU$92.38k	0.10% A$ 64.1k
Iven Klineberg	Member of the Medical Advisory Board	no data	geen gegevens	geen gegevens
J. Gerschman	Member of the Medical Advisory Board	no data	geen gegevens	geen gegevens
Peter Cistulli	Chairman of the Medical Advisory Board	no data	geen gegevens	geen gegevens
Gaetano Russo	Chairman of the Board	4.3yrs	AU$160.96k	0.64% A$ 396.2k
Benjamin Gisz	Non-Executive Director	less than a year	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SOM wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

SomnoMed Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

SomnoMed Limited, Annual General Meeting, Nov 27, 2024

SomnoMed Limited, Annual General Meeting, Nov 27, 2024

SomnoMed Limited Announces Board Changes

No independent directors

SomnoMed Limited, Annual General Meeting, Nov 24, 2023

SomnoMed Limited Announces Resignation of Hilton Brett as Non-Executive Director

Recent updates

SomnoMed Limited, Annual General Meeting, Nov 27, 2024

SomnoMed Limited, Annual General Meeting, Nov 27, 2024

Benign Growth For SomnoMed Limited (ASX:SOM) Underpins Stock's 27% Plummet

SomnoMed Limited Announces Board Changes

Full year 2024 earnings released: AU$0.10 loss per share (vs AU$0.10 loss in FY 2023)

Full year 2024 earnings released: AU$0.10 loss per share (vs AU$0.10 loss in FY 2023)

SomnoMed Limited to Report Fiscal Year 2024 Results on Aug 28, 2024

SomnoMed Limited's (ASX:SOM) Share Price Boosted 30% But Its Business Prospects Need A Lift Too

SomnoMed Limited (ASX:SOM) Shares Fly 30% But Investors Aren't Buying For Growth

New major risk - Shareholder dilution

SomnoMed Limited (ASX:SOM) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

New major risk - Share price stability

No independent directors

SomnoMed Limited has filed a Follow-on Equity Offering in the amount of AUD 22.6 million.

Price target increased by 25% to AU$2.07

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

SomnoMed Limited to Report First Half, 2024 Results on Feb 28, 2024

Market Still Lacking Some Conviction On SomnoMed Limited (ASX:SOM)

New major risk - Revenue and earnings growth

SomnoMed Limited, Annual General Meeting, Nov 24, 2023

SomnoMed Limited Announces Resignation of Hilton Brett as Non-Executive Director

SomnoMed Limited has completed a Follow-on Equity Offering in the amount of AUD 15.499249 million.

SomnoMed Limited has completed a Follow-on Equity Offering in the amount of AUD 15.498845 million.

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

SomnoMed Limited (ASX:SOM) Could Be Riskier Than It Looks

Full year 2023 earnings: Revenues in line with analyst expectations

New minor risk - Financial data availability

SomnoMed Limited to Report Q4, 2023 Results on Aug 24, 2023

Somnomed Limited Announces Executive Changes

Is SomnoMed (ASX:SOM) Using Too Much Debt?

Price target decreased by 12% to AU$1.88

First half 2023 earnings released: AU$0.047 loss per share (vs AU$0.038 loss in 1H 2022)

It's Unlikely That SomnoMed Limited's (ASX:SOM) CEO Will See A Huge Pay Rise This Year

No independent directors

SomnoMed Limited, Annual General Meeting, Nov 25, 2022

SomnoMed (ASX:SOM) Has Debt But No Earnings; Should You Worry?

Consensus forecasts updated

Consensus forecasts updated

Full year 2022 earnings: EPS misses analyst expectations

SomnoMed Limited Provides Earnings Guidance for the Year 2023

Price target decreased to AU$2.16

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

No independent directors

Global CEO recently sold AU$81k worth of stock

SomnoMed Introduces Rest Assure

First half 2022 earnings: EPS and revenues miss analyst expectations

SomnoMed Introduces Rest Assure

SomnoMed Limited to Report First Half, 2022 Results on Feb 22, 2022

SomnoMed Limited Announces World First Technology Enabled Oral Appliance

Chairman of the Board recently bought AU$499k worth of stock

Is SomnoMed (ASX:SOM) Using Debt Sensibly?

Full year 2021 earnings released: AU$0.014 loss per share (vs AU$0.007 loss in FY 2020)

Non-Executive Director recently bought AU$81k worth of stock

Full year 2021 earnings released: AU$1.38 loss per share (vs AU$0.007 loss in FY 2020)

Non-Executive Director recently bought AU$81k worth of stock

Health Check: How Prudently Does SomnoMed (ASX:SOM) Use Debt?

Could The SomnoMed Limited (ASX:SOM) Ownership Structure Tell Us Something Useful?

First half 2021 earnings released: EPS AU$0.008 (vs AU$0.014 in 1H 2020)

New 90-day low: AU$1.83

Have Insiders Been Buying SomnoMed Limited (ASX:SOM) Shares?

Is SomnoMed (ASX:SOM) Using Debt In A Risky Way?

Is SomnoMed Limited (ASX:SOM) Trading At A 38% Discount?

Somnomed Limited Appoints Karen Borg to Board of Directors, Effective November 26, 2020

New 90-day high: AU$2.45

Full year earnings released - AU$0.0069 loss per share

New 90-day high: AU$2.14

Chairman of the Board recently bought AU$203k worth of stock

New 90-day high - AU$1.58